Phyrago™ (dasatinib)
October 17, 2025
FOR IMMEDIATE RELEASE:
Onco360® Has Been Selected as a Specialty Pharmacy Partner for PHYRAGO™ (dasatinib)
Louisville, KY — October 17, 2025 — Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a pharmacy partner by Cycle Pharmaceuticals Ltd. for Phyrago™ (dasatinib) tablets. Phyrago is a kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, for adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib, and adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.1
“Phyrago provides a new option for patients diagnosed with Philadelphia chromosome-positive CML or ALL who could benefit from concomitant PPIs and H2RAs alongside their dasatinib treatment”, said Benito Fernandez, Chief Commercial Officer. “Through close collaboration with our biopharma partners, Onco360 plays a meaningful role that is rooted in the knowledge that patients and caregivers have a trusted pharmacy partner dedicated to supporting them through every step of their journey.”
Phyrago is a novel formulation of Sprycel® (dasatinib) designed to enable concomitant use with proton pump inhibitors (PPIs) and H2 receptor antagonists (H2RAs).1 Clinical data showed no significant reductions in the bioavailability of dasatinib when administered alongside PPIs or (H2RAs).
Dasatinib demonstrated manageable safety and tolerability for adverse events, most were low grade (grade 1-2). The most common adverse reactions (≥15%) in patients receiving dasatinib as single-agent therapy included myelosuppression, fluid retention events, diarrhea, headache, skin rash, hemorrhage, dyspnea, fatigue, nausea, and musculoskeletal pain.1 See the Important Safety Information for Phyrago.
Please read the full Prescribing Information for Phyrago™.
Media Contact: Benito Fernandez, Chief Commercial Officer
516-640-1332
References:
1Phyrago™ (dasatinib) [Package Insert]. Handa Therapeutics, LLC. 2025.